Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450

Cancer Biology and Therapy

Volumn 5, Issue 2, 2006, Pages 152-155

  Guo, Minzhou ^b,c   Liu, Shuang ^a,d   Herman, James G ^b   Zhuang, Hui ^a   Lu, Fengmin ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c ZHENGZHOU UNIVERSITY   (China)

^d Otsuka Beijing Research Institute   (China)

Author keywords

EGFR; Esophageal cancer; Gefitinib; Mutations

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ESOPHAGUS CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PROTEIN DOMAIN; WILD TYPE;

EID: 33644640699     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.2.2318     Document Type: Article

References (24)

1. Lu S, Lin P, Wang G, Luo X, Wu M. Comprehensive prevention and treatment for esophageal cancer. Chin Med J 1999; 112:918-23.
2. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985: Implications for prevention and projections of future burden. Int J Cancer 1993; 55:891-903.
3. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7:2-8.
4. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2000; 62:5749-54.
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39.
6. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500.
7. Takaoka M, Harada H, Andl CD, Oyama K, Naomoto Y, Dempsey KL, Klein-Szanto AJ, El-Deiry WS, Grimberg A, Nakagawa H. Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res 2004; 64:7711-23.
8. Teraishi F, Kagawa S, Watanabe T, Tango Y, Kawashima T, Umeoka T, Nisizaki M, Tanaka N, Fujiwara T. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Letters 2005; 579:4069-75.
9. Hara F, Aoe M, Doihara H, Taira N, Shien T, Takahashi H, Yoshitomi S, Tsukuda K, Toyooka S, Ohta T, Shimizu N. Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Letters 2005; 226:37-47.
10. Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T. Characterization of 21 newly established esophageal cancer cell lines. Cancer 1992; 69:277-84.
11. Katoh M. Expression of human SOX7 in normal tissues and tumors. Int J Mol Med 2002; 9:363-8.
12. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 2003; 63:7056-61.
13. Coordinating Group for Research on the Etiology of Esophageal Cancer of North China. The epidemiology of esophageal cancer in North China and preliminary results in the investigation of its etiological factors. Sci Sin 1991; 18:131-48.
14. Roskoski R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004; 319:1-11.
15. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF. High frequency of epidermal growth factor receptor mutations with complex patterns in nonsmall cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004; 10:8195-203.
16. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305:1163-7.
17. Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crino L. Akt phosphorylation and gefitinib efficacy in patients with advanced nonsmall-cell lung cancer. J Natl Cancer Inst 2004; 96:1133-41.
18. Pao W, Miller VA, Venkatraman E, Kris MG. Predicting sensitivity of nonsmall-cell lung cancer to gefitinib: Is there a role for P-Akt? J Natl Cancer Inst 2004; 96:1117-8.
19. Gandara DR, West H, Chansky K, Davies AM, Lau DH, Crowley J, Gumerlock PH, Hirsch FR, Franklin WA. Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126). Proc ASCO 2004; 23:618.
20. 1 arrest in oral squamous cell carcinoma cell lines. Oral Oncol 2004; 40:43-51.
21. Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M, Abbruzzese A, Avallone A, Comella P, Caponigro F, Pepe S, Budillon A. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 2003; 195:139-50.
22. Hirai T, Kuwahara M, Yoshida K, Kagawa Y, Hihara J, Yamashita Y, Toge T. Clinical results of transhiatal esophagectomy for carcinoma of the lower thoracic esophagus according to biological markers. Dis Esophagus 1998; 11:221-5.
23. Mu XL, Li LY, Zhang XT, Wang MZ, Feng RE, Cui QC, Zhou HS, Guo BQ. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with nonsmall cell lung cancer. Clin Cancer Res 2005; 11:4289-94.
24. Zhang XT, Li LY, Mu XL, Cui QC, Chang XY, Song W, Wang SL, Wang MZ, Zhong W, Zhang L. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced nonsmall-cell lung cancer. Ann Oncol 2005; 16:1334-42.